Bacteriophage GH15: Developing A Novel Weapon Against MRSA

Adam Card

Abstract


In recent years, numerous bacterial species have developed antibiotic resistance due to the overuse of antibiotics in the home, health care setting, and in agriculture. Alternative methods of treatment, including phage therapy (PT), have been proposed as solutions to this problem. PT is showing promise as an alternative method of treatment against the bacteria methicillin-resistant Staphylococcus aureus (MRSA). MRSA is a virulent and antibiotic resistant bacterium capable of causing infections of the skin, respiratory system, and various other body systems. In this research proposal, we propose investigating the use of the Staphylococcal bacteriophage (phage) GH15 as a therapeutic agent against MRSA infections due to its broad host range, its lack of bacterial virulence genes, and its strong ability to lyse various strains of MRSA. Specifically, we propose to evaluate the tail fibre genes of GH15 contributing to the phage’s host range, in addition to the ability of the phage to induce antiphage humoral immune responses in human cells, in the interest of exploring GH15 as a therapeutic agent for use in PT, specifically against MRSA.

 


Keywords


Bacteriophage; MRSA; phage therapy; phage GH15

Full Text:

PDF

References


Łusiak-Szelachowska. et al. Phage Neutralization by Sera of Patients Receiving Phage Therapy. Viral Immunology 2014, 27, 295-304.

Pires, D; Cleto, S; Sillankorva, S; Azeredo, J; Lu,

T. Genetically Engineered Phages: a Review of Advances over the Last Decade. Microbiology and Molecular Biology Reviews 2016, 80, 523 - 243.

Xia, F. et al. Combination Therapy of LysGH15 and Apigenin as a new Strategy for Treating Pneumonia Caused by Staphylococcus aureus. American Society for Microbiology 2015, 82, 87 - 94.

Ross, A; Ward, S; Hyman, P. More is Better: Selecting for Broad Host Range Phages. Frontiers in Microbiology 2016, 7, 1-6.

Summers, W. The Strange History of Phage Therapy. Bacteriophage. 2013, 2, 130-133.

Wittebole, X; De Roock, S; Opal, S. A Historical Overview of Bacteriophage Therapy as an Alternative to Antibiotics for the Treatment of Bacterial Pathogens. Virulence. 2014, 5, 226-235.

Wang, Z; Zheng, P; Ji, W; Fu, Q; Wang, H; Yan, Y; Sun,J. SLPW: A Virulent Bacteriophage Targeting Methicillin-Resistant Staphylococcus aureus In vitro and In vivo. Frontiers in Microbiology 2016, 7, 1-10.

Zhang, L. et al. LysGH15 Kills Staphylococcus aureus Without Being Affected by the Humoral Immune Response or Inducing In ammation. Scienti c Reports 2016, 6, 1-9.

U.S. Department of Health and Human Services. Methicillin-Resistant Staphylococcus aureus. Antibiotic Resistance Threats in the United States 2013, 77-78.

Verstappen, K; Tulinski, P; Duim, B; Fluit, A; Carney, J; van Nes, A; Wagenaar, J. The Effectiveness

of Bacteriophages Against Methicillin-Resistant Staphylococcus aureus ST398 Nasal Colonization in Pigs. PLOS One 2016, 1-10.

Gu, J. et al. Complete Genome Sequence of Staphylococcus aureus Bacteriophage GH15. Journal of Virology 2012, 86, 8914 - 8915.

Gu, J. et al. Genomic Characterization of Lytic Staphylococcus aureus phage GH15: Providing New Clues into Intron Shift in Phages. Journal of General Virology 2013, 94, 906 - 915.

Dinarello, C. Proin ammatory Cytokines. Chest. 2000, 118, 503-508.

Nobrega, F; Rita Costa, A; Kluskens, L; Azeredo, J. Revisiting Phage Therapy: New Applications for Old Resources. Trends in Microbiology 2015, 23, 185-191.

Zaczek, M; Łusiak-Szelachowska, M; Jończyk- Matysiak, E; Weber-Dąbrowska, B; Międzybrodzki, R; Owczarek, B; Kopciuch, A; Fortuna, W; Rogóz, P; Górski, A. Antibody Production in Response to Staphylococcal MS-1 Phage Cocktail in Patients Undergoing Phage Therapy. Frontiers in Microbiology 2016, 7, 1 - 14.

Gu, J; Zuo, J; Lei, L; Zhao, H; Sun, C; Feng, X;

Du, C; Li, X; Yang, Y; Han, W. LysGH15 Reduces the In ammation Caused by Lethal Methicillin- Resistant Staphylococcus aureus Infection in Mice. Bioengineered Bugs 2011, 2, 96 - 99.

Górski, A; Weber-Dąbrowska, B. The Potential Role of Endogenous Bacteriophages in Controlling Invading Pathogens. Cellular and Molecular Life Science 2004, 62, 511 - 519.

Takeuchi, I; Osada, K; Haeruman Azam, A; Asakawa, H; Miyanaga, K; Tanji, Y. The Presence of Two Receptor-Binding Proteins Contributes to the Wide Host Range of Staphylococcal Twort-Like Phages. Applied and Environmental Microbiology 2016, 82, 5763 - 7774.

Daniel-Paul, V; Sundarrajan, S; Saravanan Rajagopalan, S; Hariharan, S; Kempashanaiah, N; Padmanabhan, S; Sriram, B; Ramachandran, J. Lysis-De cient Phages as Novel Therapeutic Agents for Controlling Bacterial Infection. BMC Microbiology 2011, 1-9.

Górski, A. et al. Phage as a Modulator of Immune Responses: Practical Implications for Phage Therapy. Advances in Virus Research 2012, 83, 41 - 71.

Mahichi, F; John Synnott, A; Yamamichi, K, Osada, T, Tanji, Y. Site-Speci c Recombination of T2 Phage Using IP008 Long Tail Fibre Genes Provides a Targeted Method for Expanding Host Range While Retaining Lytic Ability. Federation of European Microbiological Societies 2009, 295, 211 - 217.

Miernikiewicz, P. et al. T4 and Its Head Surface Proteins Do Not Stimulate In ammatory Mediator Production. PLOS One 2013, 8, 1-13.

Hwang, J; Kim, J; Song, Y; Park, J. Safety of using Escherichia coli Bacteriophages as a Sanitizing Agent Based on In ammatory Responses in Rats. Food Science and Biotechnology 2016, 25, 355 - 360.

Hong, Y; Thimmapuram, J; Zhang, J; Collings, C; Bhide, K; Schmidt, K; Ebner, P. The Impact of Orally Administered Phage on Host Immune Response and Surrounding Microbial Communities. Bacteriophage 2016, 6, 1 - 9.




DOI: https://doi.org/10.13034/jsst.v11i1.244

Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Journal of Student Science and Technology